Tetratherix trades lightly as it holds A$358 million valuation
Tetratherix Ltd finished Friday with a market capitalization of A$358.0 million. Out of a total 53.04 million ordinary shares, only 29.47 million are listed.
Jupiter Neurosciences (NASDAQ:JUNS) surge cools as $100 million MDMA agreement strains funding resources
Jupiter Neurosciences shares gave up much of an earlier 67% rally on Tuesday after securing U.S. rights for a trial-stage MDMA drug. The stock was up 6.2% at $0.1752 as of 12:50 p.m. EDT.
AtaiBeckley (NASDAQ:ATAI) shares trade with Merger CVR valued near 19% of face
AtaiBeckley, previously known as Atai Life Sciences, closed at $7.22 on Friday, trading 47 cents higher than the cash element of Eli Lilly’s offer. U.S. stock markets did not open on Sunday.
ImmunityBio (NASDAQ:IBRX) stock faces July 24 warrant-expiry test after Friday rebound
ImmunityBio, Inc. enters next week with a warrant-expiry test. Up to 6.4 million new shares could emerge on Friday. That figure uses the March 31 balance.
CSL Limited (ASX:CSL) awaits US$650 million hurdle ahead of August results, pressuring rebound
CSL Limited gained 1.12% to close at A$123.32 on Friday. The S&P/ASX 200 index slipped 0.50%. Sydney’s cash market remained closed on Saturday morning.
VivoSim Labs (NASDAQ:VIVS) hits $5M milestone; company says 500% revenue jump comes off $131K base
VivoSim Labs, Inc. reported Wednesday it got a $5 million milestone payment from Eli Lilly and Company, bringing in cash worth about 1.7 times VivoSim’s equity value at Tuesday’s close and recent share count. Still, shares ended up just 3.0% at $0.8599, slipping from an open of $1.49.
AtaiBeckley Inc. (NASDAQ:ATAI) stock jumps as FDA staffing guidance spotlights BPL-003’s two-hour edge
AtaiBeckley Inc. shares climbed 15.6% to about $5.75 in Tuesday afternoon trading as investors weighed final U.S. Food and Drug Administration guidance for psychedelic-drug trials. The document expects two monitors to remain with a patient throughout a treatment session, making BPL-003’s roughly two-hour clinic model more relevant to operating costs. Duration is now a cost variable.
NextCure stock surge puts cash payout and 1.21% Avere stake under the lens
NextCure, Inc. shares nearly tripled on Tuesday after the cancer-drug developer agreed to merge with privately held Avere Therapeutics and pair the transaction with a $320 million financing. Yet current holders are expected to own just 1.21% of the combined company, making the rally a wager on a possible cash distribution, a contingent-value right and a higher public valuation for Avere—not merely the financing headline.
Virax Biolabs (NASDAQ:VRAX) Soars 183% After Fosun Deal
Virax Biolabs Group shares jumped more than 100% during Thursday’s U.S. session after the diagnostics company said its UK subsidiary reached an exclusive multi-country supply deal with Fosun Diagnostics for its ImmuneSelect research-use immune-profiling line. The Nasdaq stock was trading at $9.00 as of 11:52 a.m. EDT, up $5.82 on the day, with about 57.8 million shares changing hands.
Bluejay Diagnostics stock rally meets a June warrant wall after pre-market churn
Bluejay Diagnostics, Inc. jumped before the open on Tuesday. The rally put a tiny diagnostics stock back on active trader screens, but the sharper point was the financing math sitting above the tape.
Recursion Pharmaceuticals (NASDAQ:RXRX) stock gains as short interest and Russell flows hit AI-biotech rally
Nasdaq traded normally at the dateline after being shut July 3 for the Independence Day holiday. Recursion Pharmaceuticals, Inc. rose 4.7% to $3.98 in the latest quote, adding about $95 million in market cap at that price.
Regencell Bioscience (NASDAQ:RGC) slumps 63% under May offer after rebound fades
Regencell Bioscience Holdings Limited dropped Thursday morning after jumping on Wednesday. The move came as biotech funds traded higher. The stock is trading out of sync with the sector and is still well under the price from the company’s share sale six weeks back.
CELZ jumps before FDA update as traders weigh dilution math
Creative Medical Technology Holdings, Inc. shares surged Tuesday on Nasdaq. The Phoenix biotech pulled an equity-and-warrant registration statement that was big versus its share count.
Abivax (NASDAQ:ABVX) ADS gain $2.3B after obefazimod safety news; Paris session yet to start
Abivax S.A. is set for a lagged Paris opening after its U.S. ADS jumped in after-hours trading. Investors reacted to new clinical data on obefazimod, Abivax’s ulcerative colitis drug. The latest news hits late, but the drop earlier this month wasn’t about whether the drug works. It was about the potential cancer risk and what that could mean for the drug’s label.
Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week
Moderna, Inc. jumped 12.59% Friday to close at $67.27, snapping a stretch this week where traders mostly ignored pipeline optionality. The stock started the week at $63.96 and finished up $3.31 for the week. Most of that came Friday, when the shares rose $7.52.
SELLAS Life Sciences (NASDAQ:SLS) trades higher after new share count shows nearly $2 billion value
SELLAS Life Sciences Group Inc is up 12.6% at $10.33 in Thursday afternoon action, trading 12.2 million shares. The stock opened at $9.21, hit $11.05, and last traded at $10.33 at 2:51 p.m. EDT. Previous close was $9.17.
Bio-Techne soars after Merck offer at $73 a share; spread remains on cash bid
Bio-Techne Corporation moved into merger-arb territory Thursday morning after Germany’s Merck KGaA said it would acquire the life-sciences tools company for $73 per share in cash. Shares traded at $70.17 at 9:51 a.m. EDT, up 19.18%, leaving a $2.83 spread to the offer.
AbbVie moves to acquire Apogee in $10.9 billion bet on immunology
AbbVie said Monday it’s buying Apogee Therapeutics for $10.9 billion in cash, making this its largest deal since 2019. The company is looking to strengthen its immunology pipeline with Apogee’s long-acting immune-disease drugs. AbbVie and Apogee put out a joint release on the agreement, according to a securities filing. They expect the deal to close in the third quarter of 2026.
CervoMed rises on patent news, pares gains after $10M equity sale
CervoMed Inc. shares pulled back Thursday, erasing much of an earlier jump linked to a patent development. The Boston biotech quickly announced a $10 million stock offering, flipping the mood. Investors were left to consider potential IP gains next to the hit from dilution.
uniQure shares steady after FDA momentum, Huntington’s filing on radar
uniQure N.V. shares on the Nasdaq held much of Wednesday’s big jump in premarket trade Thursday. The U.S. FDA has cleared a route for the Netherlands-based gene-therapy firm to pursue approval of its experimental Huntington’s disease drug, AMT-130. The stock finished at $48.16 on Wednesday, climbing 78.4% from $26.99 a day before.
TechStock² Updates
